FOXO4-DRI in senescent cells: what does preclinical research show?

This Research Library page summarizes independently published research on FOXO4-DRI. For each study, it identifies the research model, key finding, and main limitation.

Study 1

Level of evidence: Cell and animal research

Topic: Disruption of the FOXO4-p53 interaction and removal of senescent cells.

Key finding: FOXO4-DRI caused selective apoptosis of senescent cells in models and improved certain tissue and functional measures in mice.

Main limitation: No clinical trial in humans; claims about human rejuvenation are not justified.

Source: Original publication via PubMed · DOI: 10.1016/j.cell.2017.02.031

Scientific scope: Research on a molecule, research model, or pharmaceutical formulation does not constitute evidence of the efficacy, safety, purity, or suitability of a commercial Peptidera product. This page does not contain treatment or usage advice.

Header image: illustrative visualization, not a research result.